{"id":"peginterferon-2a","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"10-30","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"5-20","effect":"Depression and psychiatric effects"},{"rate":"5-10","effect":"Thyroid dysfunction"},{"rate":"10-20","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon-α-2a binds to interferon-alpha receptors on cell surfaces, triggering JAK-STAT signaling pathways that induce antiviral and antiproliferative gene expression. The pegylation (attachment of polyethylene glycol) extends the drug's half-life, allowing for less frequent dosing. It is used primarily in chronic viral infections and certain malignancies where immune activation is therapeutically beneficial.","oneSentence":"Peginterferon-α-2a is a pegylated form of interferon-alpha that activates innate and adaptive immune responses to suppress viral replication and inhibit cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:45.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"},{"name":"Chronic hepatitis B virus infection"},{"name":"Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)"}]},"trialDetails":[{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT02381379","phase":"PHASE3","title":"Malaysia Stop Tyrosine Kinase Inhibitor Trial","status":"UNKNOWN","sponsor":"Ministry of Health, Malaysia","startDate":"2015-03","conditions":"Leukemia, Chronic Myeloid","enrollment":118},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03208998","phase":"PHASE4","title":"The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B Infection","enrollment":100},{"nctId":"NCT03209011","phase":"PHASE4","title":"The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy","status":"UNKNOWN","sponsor":"Yao Xie","startDate":"2016-01","conditions":"Chronic Hepatitis B Infection","enrollment":100},{"nctId":"NCT03209037","phase":"PHASE4","title":"The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B Infection","enrollment":100},{"nctId":"NCT03210506","phase":"NA","title":"The Changes of Cytokines During Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B Infection","enrollment":120},{"nctId":"NCT03210493","phase":"NA","title":"The Changes of Treg Cells Frequency and Function During Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B Infection","enrollment":120},{"nctId":"NCT03210467","phase":"","title":"The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B Infection","enrollment":120},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT01446250","phase":"PHASE3","title":"Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2011-12","conditions":"Hepatitis C","enrollment":8},{"nctId":"NCT02829775","phase":"PHASE2, PHASE3","title":"A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma","enrollment":9},{"nctId":"NCT01277601","phase":"PHASE4","title":"Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-04","conditions":"Chronic Hepatitis B","enrollment":751},{"nctId":"NCT01500772","phase":"PHASE3","title":"Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2012-03","conditions":"Hepatitis C","enrollment":6},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":74},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT01289782","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":395},{"nctId":"NCT01281839","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":394},{"nctId":"NCT00637923","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2008-03","conditions":"Chronic Hepatitis C","enrollment":112},{"nctId":"NCT01384383","phase":"PHASE2","title":"GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2011-08","conditions":"Chronic Hepatitis C","enrollment":248},{"nctId":"NCT01599130","phase":"NA","title":"Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2012-07","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT01596517","phase":"PHASE4","title":"Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2003-06","conditions":"Chronic Hepatitis C","enrollment":272},{"nctId":"NCT01220596","phase":"PHASE3","title":"Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.","status":"UNKNOWN","sponsor":"Hanyang University","startDate":"2010-06","conditions":"Hepatitis B, Chronic","enrollment":228},{"nctId":"NCT00575627","phase":"PHASE4","title":"Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2007-09","conditions":"Chronic Hepatitis C","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys®"],"phase":"phase_3","status":"active","brandName":"Peginterferon-α-2a","genericName":"Peginterferon-α-2a","companyName":"Ministry of Health, Malaysia","companyId":"ministry-of-health-malaysia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon-α-2a is a pegylated form of interferon-alpha that activates innate and adaptive immune responses to suppress viral replication and inhibit cell proliferation. Used for Chronic hepatitis C virus infection, Chronic hepatitis B virus infection, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}